Imtm Gmbh

Esparma Gmbh

Keyneurotek Pharmaceuticals Ag

Michael Taeger

Siegfried Ansorge

Gerhard Fries

Frank Striggow

Dieter Koegst

Ute Bank

Karsten Nordhoff

The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).

Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases

The invention relates to a medicament containing an effector of the glutathione metabolism together with &#x3b1;-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.

Medicament containing an effector of the glutathione metabolism together with &#x3b1;-lipoic acid for treating diabetes mellitus

Growing community of inventors

Heinrichsberg, Germany

Michael Taeger